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Abstract 
The aim of this work was to study the ability of β-cyclodextrin (β-CD) or hydroxypropyl 
β-cyclodextrin (HP-β-CD) to ameliorate the induction of gastric ulcers by a nonsteroidal 
anti-inflammatory drug, indomethacin or piroxicam, in rats exposed to restraint and hypo-
thermic stress at 4 °C. Using oral gavage, rats fasted for 72 h were administered the equivalent 
of a 100 mg/kg dose of the assigned drug, alone or with the designated cyclodextrin (CD). The 
rats were placed in suitable rodent restrainers and then placed inside a ventilated refrigerator 
maintained at a temperature of 4 °C. Six hours later, each animal was removed, anaesthetized 
with ether, and the abdomen opened. Each stomach was removed, opened along the greater 
curvature and gently rinsed with isotonic saline solution. The induced gastric ulcers were 
examined and assessed with the help of a 10x binocular magnifier. Pronounced and marked 
gastric ulceration with complete loss of the mucosa, extensive deposition of fibrin and dense 
neutrophilic infiltrate were observed in rats treated with each of the drugs alone. Treatment 
with indomethacin or piroxicam alone induced ulcer indices of 26 ± 2.3 or 14 ± 1.8, respec-
tively. However, β-CD and HP-β-CD each significantly suppressed ulceration due to restraint 
and cold stress. Rats treated with indomethacin or piroxicam in the presence of either β-CD 
or HP-β-CD exhibited normal tissues. Therefore, β-CD and HP-β-CD act as protective 
agents against gastrointestinal disorders produced by restraint and cold stress, even with the 
added stress from administration of either indomethacin or piroxicam. 
Key words: β-cyclodextrin, hydroxypropyl β-cyclodextrin, indomethacin, piroxicam, gastric ulcers, 
histological examination 
Introduction 
Although oral nonsteroidal anti-inflammatory 
drugs (NSAIDs) are effective in the treatment of a 
variety of acute and chronic pain conditions, their use 
has been associated with the induction of gastric in-
jury, which is the most common adverse effect [1]. 
Physical and psychological stresses are triggers or 
modifiers of the clinical course of gastrointestinal 




drome, or inflammatory bowel disease [2]. Stress can 
act synergistically with other pathogenic factors, such 
as Helicobacter pylori, nonsteroidal an-
ti-inflammatory drugs, or colitis-inducing chemicals 
to produce gastrointestinal disease [2]. It has been 
demonstrated that restraint and cold (4 oC), as well as 
indomethacin [3-5], can induce ulceration. 
The principal mechanism of action of all NSAIDs 
is the inhibition of the biosynthesis of prostaglandins 
by blocking the activity (selectively and/or 
non-selectively) of two isoforms of cyclooxygenase 
enzyme (COX-1 and COX-2) [6-8]. With the exception 
of aspirin, NSAIDs inhibit synthesis of prostaglandins 
(mediators of inflammation) via competition with 
arachidonic acid for the two isoforms. Generally, in 
the absence of any pathological conditions, conti-
nuous release of prostaglandins usually contributes to 
certain physiological functions in both humans and 
animals. These include inhibition of gastric acid se-
cretion, regulation of vascular tone, regulation of ren-
al blood flow, and regulation of platelet aggregation 
[11,12].  
The gastric ulcerogenic action of NSAIDs is be-
lieved to occur mainly due to their local inhibitory 
effect on gastric prostaglandin E2 (PGE2) and pros-
taglandin I2 (PGI2) that are the main inhibitors of 
gastric acid secretion [13,14]. The major contribution 
of the local ulcerogenic action of NSAIDs can be ap-
preciated from the decreased incidence of ulcers fol-
lowing the use of NSAIDs enteric coated tablets.  
CDs are non-reducing, water-soluble oligosac-
charides with nonpolar cavities that allow complexa-
tion with the nonpolar portion of many drug mole-
cules [13]. Inclusion complexes of poorly soluble 
drugs with CDs present more solubilized drug, a 
greater rate of dissolution, and a more efficient ab-
sorption after oral administration, compared to un-
complexed drug [15,16]. Toxicity tests have demon-
strated that orally administered CDs are essentially 
nontoxic, largely because they are not absorbed from 
the gastrointestinal tract [17]. Gastric ulceration in-
duced by oral administration of flurbiprofen was sig-
nificantly decreased by the presence of CDs, in par-
ticular by β-CD [18]. 
Indomethacin is one of the first an-
ti-inflammatory drugs introduced for closure of pa-
tent ductus arteriosus of newborns and treatment of 
various inflammatory conditions [13]. The complex of 
indomethacin with CDs has been well studied [19-22] 
in solution and in the solid state [13,19,20]. It accom-
plishes a 1:1 inclusion complex with β-CD or 
HP-β-CD [22] by inserting either the p-chlorobenzoic 
portion or the indole unit of the molecule into the CD 
cavity [23-25]. In addition, inclusion complexes of 
indomethacin with β-CD or HP-β-CD were prepared 
and evaluated in vivo [21,22]. These inclusion com-
plexes have the ability to reduce gastrointestinal ad-
verse effects [23,24]. 
The oxicams are a class of NSAIDs that have 
made a considerable impact since their introduction. 
However, some concern has been expressed about the 
apparent high risk of gastrointestinal side effects as-
sociated with the use of some oxicams [26]. As a re-
sult, research efforts have been directed toward iden-
tifying a chemical that combines the potency of the 
oxicam class with a reduced risk of unwanted effects. 
Piroxicam is a potent NSAID that is used in the 
treatment of rheumatoid arthritis, osteoarthritis, 
traumatic contusions, and different regional inflam-
matory disorders [27]. It was reported that the inclu-
sion complex of piroxicam with β-cyclodextrin (β-CD) 
in solution and solid states was obtained with a 1:1 
stoichiometry [18,28,29]. Moreover, the inclusion be-
haviors of piroxicam with β-CD, HP-β-CD, and car-
boxymethyl β-CD were investigated and the highest 
inclusion capacity was obtained with β-CD [30]. 
Since gastric ulceration induced by flurbiprofen 
(log P = 4.24) [31] was substantially reduced by β-CD, 
it would be appropriate to investigate the effect of 
CDs as protective agents against ulceration induced 
by more hydrophilic NSAIDs, namely indomethacin 
(log P = 3.8) [31,32] and piroxicam (log P = 0.59) [33], 
where CD inclusion becomes less important for solu-
bilization.  
The aim of the study is to compare the magni-
tude of gastric ulcers of rats under cold stress (4 ºC) 
following oral treatment with indomethacin and pi-
roxicam each alone and after complexation of each 
with β-CD or HP-β-CD.  
Materials and Methods 
β-Cyclodextrin was purchased from Acros Or-
ganics (Morris Plains, New Jersey, USA). Indometha-
cin and hydroxypropyl β-cyclodextrin with a 0.6 de-
gree of substitution were purchased from Fluka 
Chemical Company (Chemie GmbH, Buchs, Switzer-
land). CDs were used as received. Piroxicam was ob-
tained from Sigma-Aldrich Chemical Company (St. 
Louis, MO, USA). All remaining chemicals were ana-
lytical grade. 
Preparation of CD Solutions 
An aqueous solution of each CD was prepared 
by dissolving accurately weighed CDs (180 mg of 
β-CD and 300 mg of HP-β-CD) in 10 ml of distilled 
water with the aid of a UP100H ultrasonic device, 




Germany) for 5 min. In the case of β-CD, a concentra-
tion of 1.8 % w/v (16 mM) was prepared. A 30 % w/v 
(217.4 mM) solution of HP β-CD was also prepared. 
These aqueous CDs solutions in the same concentra-
tions were used to dose the rats with the drugs. 
Preparation of Piroxicam and Indomethacin 
Suspensions  
An aqueous suspension of piroxicam or indo-
methacin was prepared by spreading 250 mg of each 
drug into 10 ml distilled water. In addition, a suspen-
sion of each drug was prepared in the presence of 
either β-CD or HP β-CD by sprinkling 250 mg of each 
drug into 10 ml of aqueous CD solutions with the 
same concentrations (1.8% of  β-CD and 30% of HP 
β-CD) as described in the previous section. Ultraso-
nication was utilized to obtain a well-dispersed sus-
pension of each drug. The suspension of each drug in 
the presence of CDs was considered to contain both 
the soluble drug complex with CD and excess inso-
luble suspended particles of drug.   
Solubility Study 
The phase-solubility experiments of each drug 
(piroxicam or indomethacin) with either β-CD or 
HP-β-CD were carried out by the method reported by 
Higuchi and Connors [34] in distilled water. A series 
of volumetric flasks each containing successively in-
creasing quantities of either β-CD or HP-β-CD were 
prepared. Excess of each drug was added into each 
flask to maintain saturated conditions. All flasks were 
sonicated for 30 min at 37±1 °C. Following equili-
brium, each supernatant phase was removed, filtered, 
diluted, and assayed for the total solubilized drug 
content by UV analysis. The binding constants of each 
d r u g  w i t h  e a c h  C D  w e r e  c a l c u l a t e d  f r o m  t h e  






where So is the solubility of the drug in the ab-
sence of the CD, and K1:1 is the binding constant. 
Determination of Complexed Drug with CD 
The amount of complexed drug (piroxicam or 
indomethacin) with either β-CD or HP-β-CD, was 
determined by its distribution coefficient (partition 
coefficient) in order to estimate the ratio of 
free-to-complexed drug. An accurate concentration of 
piroxicam (1.5 x 10-4 M) or indomethacin (1.1 x 10-4 M) 
in 0.1 N HCl was prepared from which 5 ml was 
added to 5 ml n-octanol in volumetric flasks. These 
two immiscible liquids were sonicated for 15 min at 37 
± 1 °C, set aside for 1.5 h, and then the aqueous phase 
was separated using a separating funnel.  The con-
c e n t r a t i o n  o f  e a c h  d r u g  w a s  d e t e r m i n e d  i n  t h e  
aqueous phase spectrophotometrically at 338 nm and 
267 nm for piroxicam and indomethacin, respectively. 
The procedures were repeated in the presence of ei-
ther  β-CD (0.016 M) or HP-β-CD (0.030 M) in the 
aqueous phase. The total concentration of free and 
complexed drug in the presence of CDs was meas-
ured, and the ratio of the free-to-complexed amount 
was calculated. Due to the low concentration of drug 
in each phase, the partition coefficients of each drug in 
the absence and presence of CDs could be estimated 
by the ratio of the drug concentration in the octanol 
phase to the concentration in the aqueous phase.   
Experimental Animals 
Male Wistar rats (250 g body weight) were pro-
vided by the Experimental Animals Care Center 
(College of Pharmacy, King Saud University, Riyadh, 
Saudi Arabia). The animals were maintained at 22 ± 1 
°C on a 12 h light-dark cycle and allowed rat chow 
and water ad libitum. Nine groups of Wistar rats (n = 
4 animals per group) were used. The allocation of the 
animals to the groups was randomized using a stan-
dard random table. Experimental protocols were ap-
proved by the Animal Care and Use Committee and 
were in accordance with the recommendations in the 
University Guide for the Care and Use of Laboratory 
Animals. 
  Before the start of the experiments, food was 
withdrawn for 72 h but water was allowed ad libitum 
[13]. Preliminary results have revealed that the 
pre-fasting condition alone doesn’t induce ulcers, as 
evidenced by the absence of ulcers in some of the 
treated groups. It was found that the minimum expe-
rimental conditions for gastric induction in the Wistar 
rats used in this study were: fasting (72 h), hypo-
thermic restraint stress exposure, and the administra-
tion of specified doses of the two NSAIDs. 
As described in the studies by Bhargava et al. 
[14], Schmassmann et al. [35] and Brzozowski et al. 
[36], on the morning of the experiments each fasted 
rat was administered the assigned drug by oral ga-
vage in a dose equivalent to 100 mg indomethacin or 
piroxicam per kg, then restrained in an appropriate 
rodent restrainer (Harvard Apparatus, Holliston, 
Massachusetts, USA) and placed inside a ventilated 
refrigerator, model 1852G (Norfolk Marine, Ltd., 
Norwich, Norfolk, UK), maintained at a temperature 
of 4 °C. Six hours later [37], each animal was removed, 
anaesthetized with ether, and the abdomen was 
opened. Each stomach was removed, opened along 




saline solution. Each stomach was pinned out on a flat 
surface with the mucosal surface uppermost. 
Examination of Gastric Ulcers 
The induced gastric ulcers were examined and 
assessed with the help of a 10x binocular magnifier. 
To quantify the induced ulcers in each stomach, a 
modification of the scoring systems described in the 
literature [35,38-41] was employed. The induced ulc-
ers in these experiments were small spots and thus 
each was given a score between 1 and 4. Ulcers of 0.5 
mm diameter were given a score of 1 whereas ulcers 
of diameters 1 and 2 mm were given scores of 2 and 4, 
respectively. For each stomach, an ulcer index was 
calculated as the sum of the total score of ulcers. The 
cumulative ulcer index is presented as the mean (n = 
4) ± standard deviation (s.d.). 
Statistical Analysis 
All data are presented as the mean ± the stan-
dard deviation (s.d.). Significant differences between 
the different treatment groups were determined by 
one-way analysis of variance (ANOVA) using the 
SPSS® statistical package (version 10, 1999, SPSS Inc., 
Chicago, IL). Statistical differences yielding P ≤ 0.05 
were considered significant. Tukey’s multiple com-
parison post hoc test was applied when necessary. 
Histological Examination 
For histological examination, all samples (sto-
machs of the rats) were removed and fixed overnight 
in 10 % w/v formalin. Each specimen was sectioned 
and submitted totally. They were processed overnight 
and then embedded in paraffin. The paraffin blocks 
were sectioned and the slides were stained with a 
standard haematoxylin and eosin stain and photo-
graphed under 20x magnification using a Nikon Ec-
lipse 80i light microscope (Nikon Corporation, Japan) 
equipped with a digital DS-Ri1 camera.  
Results and Discussion 
The binding constants of piroxicam with β-CD 
and HP-β-CD were found to be 105 M-1 and 143 M-1, 
respectively with 1:1 stiochiometry. The amounts of 
complexed piroxicam with β-CD and HP-β-CD eva-
luated by distribution coefficient method were 20.6% 
and 44.4%, respectively. The ratio of free-to com-
plexed piroxicam was 4:1 in case of β-CD and 5:4 in 
case of HP-β-CD. The binding constant of indome-
thacin with β-CD was also determined by the solubil-
ity method in water and calculated as 278 M-1. These 
results were in agreement with those constants re-
ported by Uekama and Otagiri [18]. The amount of 
complexed indomethacin with β-CD and HP-β-CD 
was evaluated by distribution coefficient between 
n-octanol and 0.1 N HCl and was found as 8.3% and 
26.6%, respectively. The ratio of free-to-complexed 
indomethacin was 11:1 in the case of β-CD, and 3:1 for 
HP-β-CD. The lower partition coefficient of piroxicam 
in the presence of HP-β-CD, as compared to β-CD, is 
likely due to the relative complexation of the drug 
with the CDs. A similar effect of the CDs on the parti-
tion coefficient of indomethacin, albeit to a lesser ex-
tent, was observed.     
 Initial experiments using 10 or 50 mg/kg doses 
of either indomethacin or piroxicam in the absence of 
cold stress did not produce ulcerations whereas 100 
mg/kg doses induced few and insignificant ulcers. 
However, if doses of 100 mg/kg given by oral gavage 
were coupled with restraint and hypothermic stress at 
4 °C, a greater number of ulcers were produced. It 
should be noted that previous studies have pointed 
out that cold stress acts synergistically with NSAIDs 
to induce gastric ulceration [2]. This last approach was 
used in this study to induce gastric ulceration. The 
diameters of the induced ulcers ranged from 0.5 to 2 
mm. 
Treatment with indomethacin and piroxicam 
alone induced ulcer indices of 26 ± 2.3 and 14 ± 1.8, 
respectively. Complexation of each of the 
non-steroidal drugs with β-CD or HP-β-CD signifi-
cantly suppressed the induced ulcers. Rats treated 
with either β-CD or HP-β-CD alone and exposed to 
restraint and hypothermic stress gave ulcer indices of 
5.75 ± 0.9 and 2.75 ± 0.4, respectively. The cumulative 
results of these studies are shown in Table 1. The 
mean percentage reductions of the induced ulcers in 
the case of indomethacin were 75 and 86.5% following 
complexation with β-CD and HP-β-CD, respectively. 
The corresponding decreases in the case of piroxicam 
were 89.2 and 80.3%, respectively. 
In this study, administration of each of the two 
NSAIDs coupled with hypothermic and restraint 
stress clearly induced ulcers. Chemically induced 
ulcers are believed to begin by inhibition of gastric 
prostaglandins derived via both COX-1 and COX-2 
enzymes [35, 42] and increased free radical formation 
[43,44]. On the other hand, the stress-induced ulcers 
are believed to result from an increase in the forma-
tion of free radicals [45,46], an increase in gastric acid 
secretion [45,47], reduction in gastric glutathione 
content [48,49] and a decrease in gastric PGE2 pro-
duction [50,51]. CDs are not absorbed in the ga-
strointestinal tract; they only enhance the absorption 
of drugs after oral administration. Thus, it seems that 
complexing NSAIDs with β-CD or HP-β-CD acts to 
interfere or prevent the local actions of the NSAIDs 
that induce gastric ulcers through local inhibition of 




tion, reduction of gastric glutathione, and local pro-
duction of free radicals [15,16]. 
Table 1. Effect of β-CD and HP-β-CD on indomethacin 
and piroxicam induced ulcers 
Treatment   Ulcer Index 
Indomethacin  26 ± 2.3 
Indomethacin + β-CD  6.5 ± 0.9* 
Indomethacin + HP-β-CD  3.5 ± 0.3* 
Piroxicam  14 ± 1.8 
Piroxicam + β-CD  1.5 ± 0.2* 
Piroxicam + HP-β-CD  2.75 ± 0.3* 
β-CD  5.75 ± 0.9 
HP-β-CD  2.75 ± 0.4 
Cold stress  3.8 ± 0.4 
* Each of the drug and CD treatments are significantly different 
from the treatment with drug alone (P < 0.01, n = 4). 
 
Histological Observations 
The histological pattern of the mucosal speci-
mens was studied by examining the histology of the 
treated and control samples. Stomach tissue with 
mucosal ulceration was observed in indomethacin 
treated rats (Fig. 1A) with a complete loss of the mu-
cosa and neutrophil infiltration and fibrin deposition. 
At the periphery of the ulcer, the adjacent squamous 
epithelium shows regenerative changes. On the other 
hand, the mucosal ulceration in groups treated with 
indomethacin and β-CD (Fig. 1B) was focal with a 
complete loss of mucosa with fibrin deposition and 
mild neutrophil infiltration. The specimens from rats 
treated with indomethacin and HP-β-CD (Fig. 1C) 
revealed no significant ulcerations and the tissues 
were almost intact. 
Pronounced and marked stomach ulceration 
with complete loss of the mucosa, extensive deposi-
tion of fibrin and dense neutrophil infiltrate was ob-
served with rats treated with piroxicam (Fig. 2A). As 
with indomethacin, at the periphery of the ulcer, the 
adjacent squamous epithelium showed regenerative 
changes. However, rats treated with piroxicam and 
β-CD or HP-β-CD exhibited normal tissues (Figs. 2B 
and 2C). 
Those rats that served as the controls expe-
rienced the stress from restraint and cold, but not 
from treatment with an NSAID. Nevertheless, the 
specimens from these rats exhibited the same results 
seen with the additional treatment with indomethacin 
or piroxicam (Fig. 3A). Specimens from the control 
rats treated with β-CD (Fig. 3B) or HP-β-CD alone (Fig 
3C) revealed that there were no significant ulcerations 
and the tissues were almost intact. The images for 
specimens from rats treated with either β-CD or 
HP-β-CD alone provide new evidence of their safety 
when orally administered. Perhaps more importantly, 
these CDs alone are capable of providing protection 
from ulceration due to restraint and cold stress.  
 
 
Figure 1. Histopathological photographs of rat stomach 
specimens stained with hematoxylin and eosin A: from rats 
treated with indomethacin alone; B: from rats treated with 
indomethacin and β-CD; C: from rats treated with indo-






Figure 2. Histopathological photographs of rat stomach 
specimens stained with hematoxylin and eosin A: from rats 
treated with piroxicam alone; B: from rats treated with 
piroxicam and β-CD; C: from rats treated with piroxicam 






Figure 3. Histopathological photographs rat stomach 
specimens stained with hematoxylin and eosin A: from rats 
experiencing restraint and cold stress alone (X200); B: from 
rats experiencing restraint and cold stress, and treated with 
β-CD; C: from rats experiencing restraint and cold stress, 
and treated with HP-β-CD. 




Both β-CD and HP-β-CD are practically insensi-
tive to salivary α-amylase as well as stomach acid. 
They are poorly digested by pancreatic α-amylase in 
the human small intestine but might be degraded by 
the colonic flora. When either β-CD or HP-β-CD is 
administered orally, absorption is low and intact CDs 
are excreted in the feces [20]. Hence, their protection 
against gastric ulceration could be attributed to com-
petitive inclusion complexation with prostaglandins 
or mucin. Gastric ulcer prevention was evident from 
the appearance of normal tissues in rats treated with 
β-CD or HP-β-CD alone (Figs. 3B and 3C, respective-
ly). On the other hand, untreated control rats exhi-
bited marked ulceration with complete loss of mucosa 
(Figure 3A). This means that both CDs could be 
counteracting the stress-induced ulcers by inclusion 
complexation of prostaglandins or mucin. These 
proposed mechanisms are supported by the reported 
data for complexation of CDs with prostaglandins E1, 
E2, and F2,a in aqueous solutions [8,52-54].  
Conclusions 
It is clear that β-CD and HP-β-CD are safe for 
oral use. They act as protective agents against ga-
strointestinal disorders initiated by restraint and cold 
stress, or by restraint and cold stress and the 
co-administration of either indomethacin or pirox-
icam. Consequently, each of these CDs can be utilized 
in the formulation of oral preparations of indometha-
cin or piroxicam to avoid the typical ulceration side 
effects.  
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